Johnson & Johnson has announced the international expansion of its Tecnis Odyssey intraocular lens (IOL), launching the presbyopia-correcting device in Europe, the Middle East, and Canada following its successful US debut in October 2024. The full visual range IOL addresses the significant unmet need for cataract patients seeking greater spectacle independence.
Clinical Performance and Patient Satisfaction
The Tecnis Odyssey IOL demonstrates impressive clinical outcomes across multiple visual parameters. According to Johnson & Johnson's clinical data, 94% of patients were satisfied with their overall vision without glasses, while 96% expressed satisfaction with reading on smartphones or tablets. Distance vision satisfaction reached 97% among patients.
The IOL's performance extends to challenging lighting conditions, with 92% of patients satisfied with their ability to see steps and read street signs at night. Clinical studies show the device provides two times better contrast in low lighting compared to PanOptix, addressing a common concern with presbyopia-correcting lenses.
Advanced Optical Technology
Built on Johnson & Johnson's established Tecnis platform, the Odyssey IOL combines advanced optics with proprietary materials to deliver consistently clear, high-contrast vision. The device features a unique, freeform diffractive surface designed to eliminate gaps between near, intermediate, and far distances, providing continuous, uninterrupted vision at all distances.
The IOL is specifically engineered to minimize night vision disturbances, including fewer halos and glare, offering better image quality than PanOptix both day and night according to the company's comparative data.
Market Impact and Portfolio Expansion
Peter Menziuso, Company Group Chairman of Vision at Johnson & Johnson, highlighted the device's rapid market adoption: "Tecnis Odyssey IOL is the fastest growing PC-IOL in the United States, and we are excited to be making it available to more patients around the world."
The international launch strengthens Johnson & Johnson's presbyopia correction portfolio, which now includes both the Tecnis Odyssey IOL and Tecnis PureSee IOL across Europe, the Middle East, Canada, and Japan. The Tecnis PureSee IOL is also available across Asia-Pacific and Latin America, though it has not received PMA approval in the United States.
Global Availability
The Tecnis Odyssey IOL is now available in the US, Puerto Rico, Japan, and the newly added regions of Europe, the Middle East, and Canada. This expansion reflects Johnson & Johnson's strategy to meet the diverse needs of the aging global population seeking advanced cataract treatment options with reduced dependence on corrective eyewear.
